[67Cu]Cu-MeCOSar-trastuzumab

N/A

Report date: 2025/10/20 14:18:49
NME

Base Information

Drug Name[67Cu]Cu-MeCOSar-trastuzumab
Drug Alias NameN/A
ClassificationRadiation-emitting products > Nuclides > Copper > 67CuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesClarity Pharmaceuticals LtdUniversity Of Melbourne
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MelbourneClarity Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A